Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression

Figure 3

(a, b) Serum concentrations of pioglitazone in CAR^+/+ and CAR^-/- mice after 2 weeks of pioglitazone treatment. (c–h) Liver histology when serum concentration of pioglitazone was similar between CAR^+/+ and CAR^-/- mice. Serum concentration was similar between (d) and (g), and (e) and (h). (c) CAR^+/+ control (vehicle), (d) CAR^+/+ pioglitazone 10 mg/kg, (e) CAR^+/+ pioglitazone 20 mg/kg, (f) CAR^−/− control (vehicle), (g) CAR^−/− pioglitazone 1 mg/kg, (h) CAR^−/− pioglitazone 3 mg/kg.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)